The importance of measuring executive function when studying the effects of cognition-enhancing agents

Annals of Internal Medicine

Volumn 149, Issue 5, 2008, Pages 358-359

  Rockwood, Kenneth ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE;

ALZHEIMER DISEASE; BRAIN FUNCTION; COGNITION; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; HUMAN; LETTER; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 51049103620     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-149-5-200809020-00016     Document Type: Letter

References (10)

1. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-97. [PMID: 18316756]
2. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:677-85. [PMID: 15090558]
3. Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001;20:51-6. [PMID: 11359070]
4. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, et al. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2002;14:377-405. [PMID: 12426407]
5. Voss SE, Bullock RA. Executive function: the core feature of dementia? Dement Geriatr Cogn Disord. 2004;18:207-16. [PMID: 15211077]
6. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol. 2007;7:26. [PMID: 17760991]
7. Rockwood K. Quality of life outcomes. In: Rockwood K, Gauthier S, eds. Trial Designs and Outcomes in Dementia Therapeutic Research. London: Taylor & Francis; 2006:131-40.
8. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, et al. American College of Physicians/American Academy of Family Physicians Panel on Dementia. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370-8. [PMID: 18316755]
9. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ. 2006;174:1099-105. [PMID: 16554498]
10. Rockwood K, Fay S, Jarrett P, Asp E. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology. 2007;68:1116-21. [PMID: 17404193]